Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 825 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo SC injections Clear all
Completed Phase 3 Interventional Results available

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

NCT03690206
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 14, 2026, 5:04 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

NCT06602258
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2814, Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • New Haven, Connecticut • Bradenton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

NCT00822835
View directory record Official record
Conditions
Healthy Subjects
Interventions
ILV-095, Placebo
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Sep 14, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
View directory record Official record
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

NCT03385239
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases
Interventions
ISIS 678354, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

NCT02526160
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab, Placebo
Biological · Other
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

NCT06315335
View directory record Official record
Conditions
Healthy Participants
Interventions
UCB9741, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)

NCT02927210
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Dimethandrolone Undecanoate, Placebo
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

NCT04541186
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Pegozafermin, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
La Mesa, California • San Francisco, California • Clearwater, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01371305
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
BG00011, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 84 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 14, 2026, 5:04 PM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

NCT02833389
View directory record Official record
Conditions
Neuropathic Diabetic Foot Ulcers
Interventions
Placebo, UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • San Francisco, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

NCT02008279
View directory record Official record
Conditions
Healthy
Interventions
100 mg CNTO 3157, 300 mg CNTO 3157, 600 mg CNTO 3157, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 14, 2026, 5:04 PM EDT
Active, not recruiting Phase 2 Interventional

RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

NCT07009860
View directory record Official record
Conditions
Alcohol-associated Liver Disease
Interventions
Pemvidutide, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Peoria, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

NCT04773678
View directory record Official record
Conditions
Moderate to Severe Persistent Asthma
Interventions
CBP-201, Placebo
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Tucson, Arizona • Huntington Beach, California • Lancaster, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

NCT05737940
View directory record Official record
Conditions
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 14, 2026, 5:04 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NCT04048135
View directory record Official record
Conditions
NASH
Interventions
Pegozafermin, Placebo
Drug · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 14, 2026, 5:04 PM EDT
Active, not recruiting Phase 2 Interventional

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

NCT07074977
View directory record Official record
Conditions
Chronic Pruritus of Unknown Origin
Interventions
nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

NCT03464136
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
Biological
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

NCT04178967
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
40
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 14, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT05355402
View directory record Official record
Conditions
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 14, 2026, 5:04 PM EDT